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Abstract
Background: Adolescents have gained increased attention because they are the only age group where HIV related
mortality is going up. We set out to describe the level and factors associated with adherence to antiretroviral therapy
(ART) as well as the 1 year retention in care among adolescents in 10 representative districts in Uganda. In addition, we
explored the barriers and facilitators of adherence to ART among adolescents.
Methods: The study involved 30 health facilities from 10 representative districts in Uganda. We employed both
qualitative and quantitative data collection methods in convergent design. The former involved Focus group discussions
with adolescents living with HIV, Key informant interviews with various stakeholders and in depth interviews with
adolescents. The quantitative involved using retrospective records review to extract the last recorded adherence level
from all adolescents who were active in HIV care. Factors associated with adherence were extracted from the ART cards.
For the 1 year retention in care, we searched the hospital records of all adolescents in the 30 facilities who had started
ART 1 year before the study to find out how many were still in care.
Results: Out of 1824 adolescents who were active on ART, 90.4 % (N = 1588) had ≥95 % adherence recorded on their
ART cards at their last clinic visit. Only location in rural health facilities was independently associated with poor adherence
to ART (P = 0.008, OR 2.64 [1.28 5.43]). Of the 156 adolescents who started ART, 90 % (N = 141) were still active in care 1
year later.
Stigma, discrimination and disclosure issues were the most outstanding of all barriers to adherence. Other barriers
included poverty, fatigue, side effects, pill burden, depression among others. Facilitators of adherence mainly included
peer support groups, counseling, supportive health care workers, short waiting time and provision of food and transport.
Conclusion: Adherence to ART was good among adolescents. Being in rural areas was associated with poor adherence
to ART and 1 year retention in care was very good among adolescents who were newly started on ART. Stigma and
disclosure issues continue to be the main barriers to adherence among adolescents.
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Background
Worldwide, it is estimated that about 2.1 million adoles-
cents aged 10–19 years are living with HIV [1]. With im-
proved access to antiretroviral therapy (ART), most of the
children with vertical transmission of HIV will soon be-
come adolescents. About 127,000 adolescents aged 10 to
19 are living with HIV in Uganda [2, 3]. Both good adher-
ence and retention in care are a prerequisite to successful
management of adolescents living with HIV (ALHIV) [4].
Poor adherence is associated with poor treatment out-
come [5–7]. In the case of ART, optimal adherence is tak-
ing 95 % and above of prescribed medication [5, 8–10].
Poor adherence to ART could lead to drug resistance
which translates into higher costs not only to the individ-
ual but also to the national ART programs [8, 9]. This is
because when patients fail on their first line regimens,
they have to be switched to more expensive second line
drugs [11]. Adherence to ART among adolescents is also
vital in prevention of HIV transmission [12]. Retention in
care after enrollment is necessary for optimal clinical out-
comes, monitoring treatment response, social support and
education among others [13]. For those on ART, loss to
follow up implies stopping ART with resultant disease
progression, development of drug resistance and eventu-
ally increased mortality [14].
Adherence to ART among adolescents has been noted
to be low [15–20]. Moreover, some studies have indicated
that being well/healthy is associated with poor adherence
[21–23]. In Uganda, the 2013 revised national ART treat-
ment guidelines recommend that all those below 15 years
are started on ART regardless of their immunological or
clinical stage of the disease [24]. The resulting large num-
bers of healthy children and adolescents starting ART
raises concerns about adherence to medication. In 2010,
retention in care using 72 cohorts and 226,307 patients
found that the 24-month retention rate in Africa was 70 %
and 36-month estimate was 64.8 % [25]. This is an un-
acceptably low rate in resource limited settings. In Uganda,
the retention in care for 617 adolescents in The AIDS Sup-
port Organization (TASO) ART programs was 96 % at
6 months and 90 % at 12 months [26]. However, these
findings could not be generalized to the whole country
since a lot of support including home care is provided by
TASO HIV program.
In Uganda, adherence to ART is measured at each clinic
visit using pill counts and recorded on a facility held HIV
care/ART card that maintains a record of the client’s basic
information and their follow up chronic AIDS care/ART
[27]. There is therefore existing adherence data for all
those on ART in their patient records at health facilities.
Data on retention in care also exists in the national tools
located at the health facilities [28, 29]. Adherence to ART
among adolescents has been described among smaller
numbers of ALHIV [17–20]. In this study, we set out to
describe the level of adherence to ART and associated fac-
tors among ALHIV on a large scale involving several HIV
programs representing all regions in the country. We also
set out to describe the 1 year retention in care for adoles-
cents who started ART in the third quarter of 2012. The
study was strengthened by involving a qualitative aspect
to help explore the barriers and facilitators of adherence
to ART and retention in care among the adolescents.
Methods
Study design
This was a mixed methods research which employed both
quantitative and qualitative methods in a convergent de-
sign. It was carried out between December 2013 and
February 2014. There were two teams of research assis-
tants sent out to the districts. Both qualitative and quanti-
tative data collection took place at the same time in the
facilities. Some research assistants collected quantitative
data while others collected the qualitative data.
Ethical statement
Written informed consent was obtained from all ALHIV
aged 18 years and older, their caregivers and all respon-
dents of KIIs. Assent was obtained from adolescents
below 18 years and their caregivers consented before the
adolescents participated in the study. Ethical approval
was obtained from Makerere University College of
Health Sciences; School of Public Health Institutional
Review Board and Uganda National Council for Science
and Technology before data collection.
Study setting
This was a nationally representative study. Uganda has
112 districts distributed into 10 sub regions. All 10 sub re-
gions of Uganda were involved in the study. These in-
cluded West Nile, North, Karamoja, Eastern, East-Central,
Kampala, Central 1 & 2, western and South West.
Sampling procedure
To select 10 districts out of 112 districts in Uganda, one
district was purposively selected from each sub region.
These included; Arua, Gulu, Serere, Mbale, Iganga,
Kampala, Kiboga, Masaka, Kiruhura and Kabarole dis-
trict. Of the 10 districts, 30 % were randomly selected
from districts which recorded good services (levels of
Cotrimoxazole prophylaxis above 80 %, 6 months CD4
access of 80 % and linkage to care for ALHIV of 70 %).
Another 30 % were selected from those without the
good services and the rest were districts with unique sit-
uations according to the baseline quantitative adolescent
survey by the Uganda Ministry of Health (MOH) [30].
In each district, only health facilities offering ART ser-
vices for adolescents were selected. Of these, one had to
be a hospital, one a Health Center (HC) IV and a HC III
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so that different facility levels were covered. Due to lo-
gistics, it was predetermined that we study only 30
health facilities. We purposively selected 10 hospitals of
which 5 were Regional Referral Hospitals. To make 10
HC III and 10 HC IVs, we purposively selected one HC
III and HC IV, from each of the 10 districts. By stratified
sampling, selection of facilities was made in a way to
capture those who had good services for ALHIV accord-
ing to the baseline quantitative survey as earlier de-
scribed, and those who do not. The selection was also
made in such a way that public and private, various im-
plementation partners were involved so that we get a
better understanding of the various settings.
Quantitative component
Selection criteria
For the quantitative part, all 30 health facilities were
included.
Study variables
These included recorded adherence to ART at the last
clinic visit, 1 year retention in care and factors associ-
ated with adherence to ART.
Data collection
Records on adherence to ART were available in 29 of the
30 health facilities. Adherence to ART was assessed in 29
health facilities using retrospective records review. The
HIV care/ART cards belonging to all adolescents who were
active in care (have visited the facility in the last 3 months)
at the time of data collection were selected and the adher-
ence level at the last visit was extracted. Factors associated
with ART adherence like the patient’s sex, age at last visit,
age at ART initiation, date of birth, date of ART initiation
and ART regimen were extracted. In Uganda, at all HIV
clinic visits, the attending Health care provider assesses
adherence to ART by pill counts and records appropriately
whether “GOOD”, “FAIR” or “POOR”adherence on the
HIV care/ART card. Good adherence refers to ≥95 % ad-
herence, fair refers to 80–95 % while poor adherence is
less than 80 % [21]. The recorded adherence level at the
last visit was extracted and recorded on a study tool. In
the large volume ART clinics, electronic records are used.
In that case, adherence levels and factors were extracted
from electronic records.
All 30 health facilities were assessed for retention in
care. To assess retention in care, the number of ALHIV
on ART still active in care after 1 year was described.
One cohort which started ART in the quarter (July to
September 2012) in all the 30 health facilities was traced
from the health facility records to find out the loss to
follow up 1 year later. This was done after eliminating
those who were transferred out and those who died. Fac-
tors that could influence retention in care like CD4
counts at initiation, clinical stage at initiation, age and
regimen at initiation and entry point to HIV care were
also extracted from the hospital registers.
Data management and analysis
Quantitative data was entered into an Epi-data (version
3.1) database which was designed with appropriate con-
trols and validation checks. Some of the adherence data
from the large programs was electronic. Analysis was done
using STATA 10.0 (College Station, TX, USA). Quality as-
surance was ensured by using a multi-disciplinary research
team, pre-testing the data collection tools, training the re-
search assistants, crosschecking all questionnaires for
completeness before leaving the health facility and field
supervision during data collection.
Qualitative component
Sampling
Of the 10 districts involved in the study, ALHIV were
selected from 5 purposively selected districts. These
were selected to cater for urban and rural adolescents,
various Implementing Partners and providers whether
government or private. The 5 selected districts included;
Kampala, Kiboga, Gulu, Mbale and Kiruhura districts.
The 69 respondents of KIIs and 40 respondents of the
IDIs involved all the 10 districts.
Selection criteria
Only ALHIV who knew their HIV status were selected in
order to avoid accidental disclosure of HIV status. In depth
interviews (IDI) were carried out involving four categories
of adolescents from each of the 10 districts; ALHIV who
are lost-to-follow-up from HIV care, adolescents in long
term relationships/married/cohabiting, in-school and out-
of-school adolescents. Key Informant Interviews (KII)s
with major stakeholders in adolescent health at the differ-
ent levels. Policy level respondents included 3 ministries;
Ministry of Health, Ministry of Education and Sports and
Ministry of Gender, Labour and Social development. At
the Local government, we interviewed District Education
Officers, District Health Officers, HIV focal persons and
politicians. Some development partners, United Nations
Agencies and donors and Implementing partners were also
interviewed. Relevant community members from schools
(school teachers, Head teachers and school nurses), reli-
gious leaders, local politicians, village health teams and
relevant Civil Society Organizations were interviewed. At
facilities, a variety of health workers involved in HIV care,
counselors and heads of hospitals and other health facil-
ities were interviewed.
Data collection
We conducted 33 Focus Group Discussions (FGD) involv-
ing 227 ALHIV and 5 FGDs with 46 caregivers of ALHIV.
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Adolescent FGDs were held in homogeneously consti-
tuted categories according to sex and age in order to allow
exploration of age and gender specific needs, perceptions
and experiences. Two age group categories were used;
young adolescents aged 10 to 14 years and older ones aged
15 to 19 years. We also included one FGD from each of
the 5 selected districts for caregivers of ALHIV. FGD data
collection took place at the health facilities. All the discus-
sions were guided by a moderator who used a FGD guide,
and had an observer who took additional notes. Anonym-
ity was maintained and confidentiality was ensured and
discussions took place in the appropriate local languages.
We conducted 69 KII and 40 IDIs. The ALHIV who
were lost to follow up were identified from facility re-
cords and then traced with the help of community vol-
unteers working with the facilities. Both the KIIs and
IDIs helped identify barriers to adherence among differ-
ent categories of ALHIV. All FGD, IDI and KII sessions
were audio taped and transcribed.
Data management and analysis
For the qualitative part, transcription of all the recordings
was done. After that, all transcripts were translated into to
English. Analysis of transcripts was done using Computer
based analysis; Atlas-ti software. We used a team ap-
proach to analyse this data. First, an analysis plan was de-
veloped based on study objectives. Then we generated a
coding scheme after reading a few transcripts. Our team
agreed on the code definitions to avoid double meanings.
This approach enhanced coding consistency. We created
a project in Atlas.ti. We used the developed codebook but
allowed open coding for emerging codes which were
agreed and hermeneutic units developed. The codes were
independently examined by an independent reviewer who
was not part of the team. We run query reports for each
theme and used them in writing the results. Primary docu-
ments matrices were also produced and patterns in the
data observed.
Quality assurance was ensured by using a multi-
disciplinary research team, training of all research assis-
tants before data collection and field supervision during
data collection. For the qualitative part, all FGDs, KIIs
and IDIs were audio recorded to allow for accurate tran-
scription. Furthermore, two independent raters analyzed
the data in order to increase reliability. In addition, all
the FGD guides and the IDI guides were translated to
the appropriate local language.
Results
Quantitative results
Altogether, there were 1824 ALHIV who were active in
HIV care in the 29 health facilities. One facility did not
have data on adherence to ART. Table 1 shows the baseline
characteristics of the ALHIV who were included in the
study. Majority of those receiving ART were girls (62.6 %)
and almost half were receiving care from RRHs and major-
ity (62.7 %) were from government facilities. Most adoles-
cents started ART late at 11 years of age on average and
majority had been taking ART for only 2 years.
Level of adherence to ART
Adherence to ART was generally good in this study as
summarized in Fig. 1. Overall, of the 1824 ALHIV,
87.1 % (N = 1588) had good adherence recorded on their
ART cards at the last clinic visit. However, on exclusion
of the 68 who had no adherence records, 90.4 % had
good adherence recorded on their ART cards. We found
that 6.5 % (N = 118) recorded fair adherence and 2.7 %
(N = 50) recorded poor adherence at the last clinic visit.
Missing records were only 68 (3.7 %).
Factors associated with adherence to ART
Factors significantly associated with poor adherence to
ART on bivariate analysis included male sex, private
health facilities, health centers, rural health facilities, less
than 1 year on ART and under 3 years on ART. The ART
regimen at initiation did not affect adherence as shown in
Table 2 below. However, on multivariate analysis, only lo-
cation of facility remained statistically significant, with
rural health facilities being associated with poor adherence
(adjusted OR 2.64 [1.28 5.43], P value = 0.008).
Retention in care
Adolescents were generally testing and enrolling in HIV
care late. Table 3 below shows that adolescents generally
enroll in care at 12 years and start ART at a median age
of 14 years. The girls are slightly older than the boys at
testing, enrolment and starting ART. Adolescents also
start ART at a low mean CD4 of 278 cells.
Table 1 Characteristics of ALHIV active on ART in the Health
facilities
Variable Frequency Percent
Sex Female 1142 63 %
Male 682 37 %
1824 100 %
Level of health facility Health Centre III 24 1 %
Health Center IV 187 10 %
HOSPITAL 60 3 %
RRHa 888 49 %
Special Clinic 665 37 %
1824 100 %
Health facility ownership Government 1144 63 %
Private 680 37 %
1824 100 %
a is a regional referral hospital
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Retention in care after 1 year was good in this study as
shown in Table 4. Of the 156 who adolescents were
started on ART in the third quarter of 2012, only 1 %
(N = 2) died and 5 % (N = 7) were lost to follow up 1
year later. However, the “loss to follow up” numbers
were too low to have meaningful statistical analysis. Ma-
jority of those who started (54 %) had World health
Organization (WHO) clinical stage II. The table also
shows that there were many more girls who started ART
than boys at a ratio of 2:1.
Fig. 1 Flow diagram showing adherence to ART among the adolescents involved in the study
Table 2 Factors associated with Non-adherence to ART in bivariate and multivariate analysis
Variable Non adherence
N = 168 (9.6 %)
Adherence





P value Adjusted OR (95 % CI) P value
Sex Female 93 (8.5) 1003 (91.5) 1096
Male 75 (11.4) 585 (88.6) 660 1.38 [1.00 1.90] 0.048 1.33 [0.84 2.13] 0.224
Facility location Urban 132 (8.4) 1441 (91.6) 1573
Rural 36 (19.7) 147 (80.3) 183 2.67 [1.78 4.01] 0.000 2.64 [1.28 5.43] 0.008
Age at initiation <15 years 122 (9.1) 1224 (90.9) 1346
≥15 years 46 (11.2) 364 (88.8) 410 1.27 [0.88 1.81] 0.195
Age at last encounter <15 years 89 (10.4) 765 (89.6) 854
≥15 years 79 (8.8) 823 (91.2) 902 0.82 [0.60 1.13] 0.237
Ownership of Health Facility Government 88 (7.9) 1022 (92.1) 1110
Private 80 (12.4) 566 (87.6) 646 1.64 [1.19 2.25] 0.002 0.55 [0.06 4.77] 0.585
Level of HF Hospital 52 (5.6) 874 (94.4) 926
Health Center 37 (18.6) 162 (81.4) 199 3.83 [2.43 6.04] 0.000 2.02 [0.97 4.22] 0.061
Duration on ART >1 year 85 (8.2) 949 (91.8) 1034
≤1 year 83 (11.5) 639 (88.5) 725 1.45 [1.05 1.99] 0.022 1.56 [0.81 3.02] 0.183
>3 years 42 (7.0) 559 (93.0) 601
≤3 years 126 (10.9) 1029 (89.1) 1155 1.63 [1.13 2.34] 0.009 0.63 [0.31 1.27] 0.195
Regimen at initiation EFV based 82 (10.3) 718 (89.7) 800
NVP based 82 (9.1) 821 (90.9) 903 0.87 [0.63 1.20] 0.415
LPV/r based 4 (11.1) 32 (88.9) 36 1.09 [0.37 3.17] 0.868
HF health facility, EFV Efavirenz, LPV/r Lopinavir/ritotanir, NVP Nevirapine
The value in bold is the only one which is statistically significant and was intentionally put in bold in order for it to stand out
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Qualitative results
Barriers to adherence to ART
Adherence challenges reported in the order of import-
ance by ALHIV and their caretakers included stigma,
laxity, poverty, side effects, disclosure challenges, pill
burden in that order were the main challenges to ART
adherence. On the other hand, service providers and
Implementing Partners reported disclosure challenges as
the main barrier to adherence.
Stigma Further qualitative analysis shows that most re-
spondents reported stigma as one of the biggest challenges
to adherence to ART. Stigma is a hindrance to disclosure
because ALHIV fear rejection by their friends, ridicule
and discrimination. They experience statements like; “You
are positive, you have no use in future” [IDI-Gulu-
ALHIV-Female]. Others said they felt stigmatized by
neighbors who whenever they would see them going to
the health facility they say, “…..there goes the HIV positive
one going to get ARV drugs”. FGD females ALHIV Gulu.
Because of stigma, some ALHIV fear to take ARVs and
may avoid the HIV clinic out of fear of meeting familiar
people who would spread the news.
Barriers to adherence at home The situation at home
may be a hindrance to adherence. For instance, some of
those staying with non biological parents as caregivers
expressed mistreatment and abuse from them. Some of
these caregivers are insensitive and they publicly disclose
the HIV status of ALHIV. Others expressed being dis-
criminated by their HIV negative siblings. One female
ALHIV said, “… they isolate us by refusing to share razor
blades or safety pins with us. They do not want to sleep
with us or even eat food with us. They fear to touch my
plate and keep it separate from others (plates)”. IDI fe-
male ALHIV Kiboga Lack of privacy in homes also hin-
ders adherence to ART. In addition, older caregivers like
grandparents forget clinic appointment dates.
Disclosure issues The fear of rejection by their partner
is a big hindrance to disclosure. Some boys said that
they would rather have pleasure with girls than receive
ART with a risk of their HIV status being discovered.
Non disclosure to partners is a hindrance to adherence
and retention in care. One adolescent girl said, “For me,
it has ever happened to me. When I was living with my
boyfriend, I used to take my medicine in hiding because I
never wanted him to know that I had HIV. When the
medicine got finished, I feared to go to the hospital to get
more. That is how I stopped taking medicine (ARVS) for
about two months.” FGD ALHIV-Gulu. Delayed disclos-
ure of HIV status by parents or guardians also leads to
poor adherence. One caregiver feared to tell the child
because she thought he could easily hurt himself.
Table 3 Characteristics of Adolescents who started ART in the
3rd Quarter of 2012
Variable Mean Median (IQR)
Age at testing for HIV Female 13 14 (10 17)
Male 11 11 (9 14)
All 12 12 (10 16)
Age at enrolment in
HIV care
Female 13 14 (10 17)
Male 11 11 (9 14)
All 12 12 (10 15)
Age at ART initiation Female 14 15 (12 17)
Male 13 13 (11 15)
All 14 14 (11 17)
CD4 at ART initiation All 278 277 (164 348)
Variable Frequency Percent
Sex Female 105 67 %
Male 51 33 %
Total 156 100 %
Age groups 10 to 14 81 52 %
15 to 19 75 48 %
Total 156 100 %
WHO staging at ART
Initiation
I 15 9 %
II 84 54 %
III 37 24 %
IV 14 9 %
Missing 6 4 %
Total 156 100 %
Level of health facility Health Center III 1 1 %
Health Center IV 24 15 %
HOSPITAL 9 6 %
RRH 49 31 %
SPECIAL CLINIC 73 47 %
Total 156 100 %
Health facility ownership Government 82 53 %
Private 74 47 %
Total 156 100 %
RRH Regional Referral Hospital
Table 4 One year Outcome of the adolescents who started ART
in 3rd Quarter of 2012
Outcome Frequency Percent
Alive 141 90 %
Dead 2 1 %
LTFUa 7 5 %
Stopped 0 0 %
Transferred out 6 4 %
Total 156 100 %
aLoss to follow up
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Barriers arising from characteristics of adolescent
stage Self image, identity and peer pressure were men-
tioned as barriers to adherence. One caregiver said that
identity and self image affect adolescents and can there-
fore be a barrier to adherence. He stated, “For example if
one makes a comment to an adolesccent that, “You used to
have good skin, how come you are now dark? You might be
sick”. This could lead them to abandon the medicine; per-
ceiving them as the cause of their skin and body changes.
So they leave them.” FGD caregivers Kiruhura. Others
said peer pressure could lead an adolescent to take drugs
of abuse like marijuana and go for dances which could
stop them from taking their ARVs.
Depression and frustration Caregivers also reported
that some adolescents feel that they are as good as dead
and are therefore not motivated to take the medicine.
“Some youths rationalize that since the medicine does
not remove the virus from their bodies, they either leave
it completely or they swallow haphazardly. They do not
appreciate the benefits of taking the medicine. They take
it when they remember; but if they forget and don’t take
it, no problem”. FGD caregivers Kiruhura.
Barriers at school or work Adolescents reported stigma
and discrimination at school by teachers and fellow stu-
dents. Those in boarding schools lacked privacy to take
their medication, which leads to missing doses. For those
who do not disclose their HIV status to the school au-
thorities, it is very difficult to get permission to leave
school to keep a clinic appointment. This could lead to
absenteeism and eventually drop out from HIV care. For
the working adolescents, they do not have job security
and they perceive that people label them as weak and do
not want to employ them.
Fatigue Some ALHIV start ART when they are weak
and at that point they have good adherence. As they im-
prove, their commitment to taking the medication re-
duces. One hospital administrator said that laxity was
inevitable among adolescents since they are still young
and short sighted about their future. Others said that be-
cause some ALHIV look very good, they do not seem to
appreciate the need to keep taking medication. Adoles-
cents reported that by nature they are very playful and
easily forget their medication. For instance, some prefer
to go to games instead of going to receive treatment.
Adolescent girls said that some boys stubbornly refuse
to take the medicine as stated, “…if it meant death let
them die”. FGD ALHIV-females Kampala. They re-
ported that some adolescents were proud and felt they
did not need to swallow drugs. Others simply stopped
taking the medication out of fatigue especially among
those who started when they were still young as sug-
gested by an official from the Ministry of Health.
Poverty All the focus groups and key informants men-
tioned poverty as a key factor in ART adherence. Be-
cause of poverty, some of them lacked food and they
report abdominal pain whenever they take the medicine
on an empty stomach. Coupled with lack of transport to
the facilities especially in the rural areas, this leads to
loss to follow up or poor adherence to treatment.
Barriers due to the ARVs Adolescents reported that
side effects, drug palatability and pill burden are a hin-
drance to adherence. Others said that some of the medi-
cines have a terrible smell and they could not take them.
They feel like the medicine is “torturing” them. During
FGDs with ALHIV, they indicated that taking the pills
every day and on time was very difficult since ARVs do
not result in a cure. The many tablets, the unpalatable
taste, the size and colour caused a lot of distress. One
male ALHIV said, “There are some ARVs that are big.
They may tell you to swallow 2 in the morning, 2 in the
evening. …How can I swallow these drugs for the rest of
my life? Moreover I am not going to change my HIV sta-
tus. That is why some people stop taking ARVs.” IDI
ALHIV-male-in-school Mbale.
Lack of psychosocial support This was mostly men-
tioned by health care providers, and other key informants.
They indicated that there was no adequate psychosocial
support to meet the needs of teenagers about adherence
especially for those who attend boarding schools and take
ARVs.
Myths and misconceptions Few focus groups and key
informants mentioned this as a barrier to adherence.
Some thought that if they took ARVs for some time the
virus would die and they would live a normal life. Others
doubted their HIV results and were not eager to take
the drugs. Others believed in faith healing and stopped
taking medication. Some adolescents have misconcep-
tions that ARVs kill or are so strong that they make
them sicker. One village leader said there was a percep-
tion on their village that whoever tested positive would
be given medication to kill them very quickly and this
would discourage them from taking ARVs.
Facilitators of adherence and retention in care
Adolescents and their caregivers reported that peer sup-
port groups are very supportive of adherence. Presence
of counselors and caring health workers also helps them
to adhere to their medication. Other facilitators included
scheduling clinic visits during school holidays, providing
food support, transport to clinics, short waiting time,
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telephone calls from the facilities and text messages.
Some programs motivate adolescents by teaching them
skills and engaging them in income generating activities.
One urban program engages adolescents in conversa-
tions with other ALHIV in other countries through so-
cial media like google hang out and “facebook”.
Discussion
On exclusion of the 68 who had no records on adher-
ence level, 90.4 % of those who had an adherence record
had good adherence. This level of adherence was higher
than expected for adolescents because when compared
with younger children and adults, HIV-infected adoles-
cents and young adults consistently have disproportion-
ately higher rates of poor drug adherence and virological
failure [12, 31]. Most studies have found the 95 % adher-
ence levels by pill counts among adolescents to range
between 65 and 80 % [12–14, 16]. It may have been
higher in our study because of the method used to assess
adherence whereby we used records. This assessment is
made by clinicians during their routine clinical practice
and not study settings. To note, most HIV clinics are
heavy and health workers may not be in position to ac-
curately assess adherence by counting all pills balances
from all patients. In addition, studies show that pill
counts method of adherence assessment can be manipu-
lated and adherence has been found to vary with the
method of assessment used [16, 17]. A similar study
among adolescents receiving ART at the Joint Clinical
Research Centre in Kampala, Uganda, found that 93, 67
and 23 % of patients had an adherence of greater than
95 % as measured by self-report, clinic based pill counts
and electronic cap methods, respectively [16]. This study
had much lower adherence levels by pill counts than our
study. In addition, about two thirds of the adolescents
were on ART for less than 3 years. Studies show that ad-
herence to ART gets worse with time [32].
Adherence was worse among the rural compared to
urban living adolescents. This was contrary to findings
in a cohort study from 2006 to 2011 which was con-
ducted among 1000 children resident in urban and rural
settings of Uganda to compare the response to ART
among urban versus rural children and the factors asso-
ciated with this response. Adherence of ≥95 % was ob-
served in 88.2 % of urban versus 91.3 % of rural children
by self-report, and in 78.8 % of urban versus 88.8 % of
rural children by pill counts. This study also reported
that rural children had more favorable clinical outcomes
and were more likely to adhere optimally to ART than
urban children [33]. However, our study consisted of ad-
olescents who are a special group that needs a lot of psy-
chosocial support. The urban located facilities in our
study had more adolescent friendly services, peer sup-
port groups and more innovations to support ALHIV
than in the rural facilities which could explain the better
adherence. Studies show that adolescents are attracted
to such adolescent friendly services [34, 35].
One year retention in care was very good in this study
with only 5 % lost to follow up and 1 % mortality. We
could not analyze the factors associated with loss to follow
up since the numbers were too few. The retention in care
could have been very good because almost 80 % of the
ALHIV were in special clinics and RRHs which have a lot
of support from partners in terms of making services ado-
lescent friendly, telephone follow up, providing food and
even transport in some programs. Studies have shown that
support given to clients improves retention in care [14].
Retention in care was much higher than what studies in
Africa have shown [19]. However, it was similar to what
was found in TASO ART program where retention was
96 % at 6 months, 90 % at 12 months, 83 % at 24 months,
76 % at 36 months, and 71 % at 48 months [20]. The study
period of 1 year could be responsible for this finding and
retention would probably reduce with time. Furthermore,
studies show that being on ART is associated with better
retention in care. [36]. In our study, we only involved
ALHIV who were taking ART. Our mortality rate was very
low, contrary to what studies show that the mortality
amongst ALHIV is high [37]. For instance, one observa-
tional prospective cohort study of adolescents and adults
with HIV (>15 years) at a community-based ART clinic in
South Africa reported the probability of death in the first
year of ART (7.9, 95 % CI 7.0–8.9 %) [38]. This difference
could be because 63 % of ALHIV started ART with WHO
clinical stage 1 and 2 and 68 % were attending care at spe-
cialized HIV clinics and Regional referral clinics, coupled
with the high levels of ART adherence from our study.
From the qualitative component of the study, several
barriers to adherence were reported in the homes, school
and health facility. Among them, disclosure, stigma and
discrimination were the most predominant barriers. Dis-
closure has been described to be a facilitator of adherence
among children [39]. Similar to other studies, the chal-
lenges to ART adherence among ALHIV were multifactor-
ial and included family situations, socioeconomic factors,
medication issues and healthcare systems [40–43].
The strength of this study is that it had both qualitative
and quantitative aspects which yielded very helpful data. It
involved the ALHIV, their caregivers, schools and others
in the education sector, various health workers and re-
source persons. It also had good representation since all
10 sub regions of the country were involved in the study.
Furthermore, rural and urban as well as public and private
facilities were included in the assessment. However, we
encountered a few limitations. First, we used the recorded
adherence level from the clinical records which may not
be as accurate as measuring adherence in a study setting.
However, since these records are available and adherence
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is assessed at every visit, it was important to use them to
describe the adherence levels from a large sample of
ALHIV. We also found gaps in the data for the retrospect-
ive records review. Lastly, information was gathered from
only 10 out of 112 districts in the country due to limited
resources. However, efforts were made to ensure regional
representation by involving one district per region.
Conclusion
Adherence to ART among adolescents was very good with
over 90 % recording good adherence. Adolescents residing
in rural areas have less support and were associated with
poor adherence. Stigma and discrimination were the main
barriers to adherence amongst adolescents. One year re-
tention in care was very good with 90 % of ALHIV still
alive and in care 1 year later. We recommend another
study to describe the retention in care for adolescents
after longer durations on ART.
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